# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN-TD
- Date: 1955-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She has been worn out for two months, bruises easily and her gums bleed; she suspects her blood and wants to know at once **S**
- She knows the long-term effects of radiation on the bone marrow from her own field and from her mother's illness, and wants her exposure history taken seriously **S**

## Your goals

- Diagnosis, classification and a treatment decision within two weeks of the first visit. Target: 1955-09-28. Recorded outcome: Marrow two days after the first visit; genetics back and treatment started on day 14. **S**
- Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding. Target: 1955-10-30. Recorded outcome: No tumor lysis; no fever or fungal infection; no bleeding beyond bruising; one outpatient visit for nausea. **S**
- Remission on the response assessment after cycle 1 (ELN 1951 complete remission, or complete remission with partial hematologic recovery). Target: 1955-10-30. Recorded outcome: Day-22 marrow blasts 3%; at day 33 neutrophils 0.9 and platelets 88: complete remission with partial hematologic recovery, measurable residual disease positive. **S**
- Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle. Target: 1955-09-28. Recorded outcome: Seen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visit. **S**
- Her occupational dose records obtained and the exposure history documented. Target: 1955-10-30. Recorded outcome: Records requested in writing from the employer's radiation safety office; history documented. **S**

## What we agreed to do

- Urgent evaluation of pancytopenia with blasts on the smear: peripheral smear review, comprehensive metabolic panel, LDH and uric acid today; coagulation tests at the hematology visit; no aspirin or anti-inflammatory drugs; go to the emergency department at once for a temperature of 38.0 °C or more, bleeding that does not stop, or new confusion or headache. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026) **S**
- Urgent hematology/oncology consultation within two days for suspected acute leukemia: bone marrow biopsy, classification and treatment plan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026) **S**
- Occupational health history: her work with X-rays, polonium and other sources over about four decades, and the sealed-source accident in her laboratory, documented; written request to the employer's radiation safety office for her dosimetry and bioassay records, which the employer must keep and must furnish on request. Guideline: 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026) **S**
- Transfusion support: irradiated, leukoreduced products; red cells one unit at a time for hemoglobin below 7 to 8 g/dL or symptoms; platelets for a count below 10 x10^3/uL, for bleeding, or before procedures that need them. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015) **S**
- Pre-treatment work-up: HLA typing for a future transplant, hepatitis B, hepatitis C and HIV testing, chest X-ray because of past tuberculosis, echocardiogram, lung function tests with diffusing capacity, and a dental check. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020) **S**
- Induction with azacitidine 75 mg/m2 on days 1 to 7 and venetoclax ramped up to 70 mg daily (the dose for use with posaconazole), in 28-day cycles; admitted for the ramp-up with tumor lysis monitoring, allopurinol and fluids; bone marrow at day 21 to 28, holding venetoclax if blasts are below 5% until counts recover; later cycles with 21 days of venetoclax. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020) **S**
- Infection prevention: posaconazole, acyclovir, and levofloxacin while neutrophils are below 0.5; a written fever plan (temperature of 38.0 °C or more: go to the emergency department for antibiotics within one hour); hand hygiene and food safety. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018) **S**
- Specialist palliative care alongside treatment from the first cycle: symptoms, prognosis in plain numbers, her goals and values, and advance care planning, reviewed at every visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024) **S**
- Allogeneic stem cell transplant evaluation by the transplant center from the first cycle: an unrelated donor search from her HLA typing, reduced-intensity conditioning if she reaches remission, and measurable residual disease monitoring. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022) **S**
- Nausea and constipation during cycle 1: ondansetron as needed after a normal QTc, with no other QT-prolonging antiemetic; polyethylene glycol and senna by mouth, no rectal medicines while neutropenic; potassium replaced; red cells and platelets given; venetoclax continued with food. Guideline: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020 (PMID 32658626) (2020) **S**

## Follow-up

- 1955-09-14: New patient visit for two months of tiredness, bruising and bleeding gums: blood count with blasts on the smear, and urgent hematology referral **S**
- 1955-09-16: Hematology consultation and bone marrow biopsy: diagnosis of acute myeloid leukemia, transfusion, and pre-treatment work-up **S**
- 1955-09-28: Genetic results, classification and risk, fitness for treatment, early palliative care, and day 1 of azacitidine with venetoclax **S**
- 1955-10-19: Day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery **S**
- 1955-10-26: Periodic adult preventive visit during AML therapy **S**
- 1955-10-30: Count recovery and response assessment; cycle 2; transplant evaluation; occupational dose records **S**

This teaching document does not replace care from a qualified clinician.
